ETAS reduces wake time after sleep onset in healthy adults dissatisfied with their sleep
In a randomized, placebo-controlled, double-blind crossover study, 14-day intake of ETAS (300 mg/day as ETAS50) did not significantly change the proportion of N3 sleep but significantly reduced wake time after sleep onset (WASO) and total time of N1 sleep. It also improved AIS scores for total score, awakenings during the night, and daytime functioning. Post-hoc analysis showed significant reductions in WASO for those with high baseline WASO and improved sleep efficiency in those with low baseline sleep efficiency.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
ETAS reduces wake time after sleep onset in healthy adults dissatisfied with their sleep The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 42/100 (low).
The Claim
ETAS reduces wake time after sleep onset in healthy adults dissatisfied with their sleep
This conclusion is most relevant to: 38 healthy adults with sleep dissatisfaction.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸ETAS reduces wake time after sleep onset in healthy adults who are dissatisfied with their sleep: A randomized, placebo-controlled, double-blind crossover study. (Sleep medicine: X, 2026) —
How It Works
The proposed biological pathway:
- ▸ETAS intake over 14 days
- ▸Modulation of sleep architecture
- ▸Reduction in wake time after sleep onset and N1 sleep
- ▸Improved subjective sleep quality and daytime functioning
Who Might Benefit
Evidence fit by population:
- ▸38 healthy adults with sleep dissatisfaction
Recommended Dose
300 mg/day as ETAS50
Limitations & Caveats
Important context when interpreting this evidence:
- ▸No significant effect on primary endpoint (N3 proportion)
- ▸Post-hoc subgroup analyses were not pre-specified, increasing risk of type I error
- ▸Short intervention period (14 days) and small sample size
Frequently Asked Questions
What is ETAS?▼
ETAS is a standardized extract of Asparagus officinalis stem, studied for its potential to improve sleep quality.
Did ETAS improve deep sleep (N3)?▼
No, the study found no statistically significant difference in the proportion of N3 sleep after 14 days of ETAS intake.
What sleep parameters did ETAS improve?▼
ETAS significantly reduced wake time after sleep onset (WASO) and total time of N1 sleep, and improved AIS scores for total score, awakenings during the night, and daytime functioning.
Who might benefit most from ETAS?▼
Post-hoc analysis suggests that individuals with high baseline WASO may see significant reductions in WASO, and those with low sleep efficiency may see improvements in sleep efficiency.
References
- 1.Misu M, Goto K, Takanari J. “ETAS reduces wake time after sleep onset in healthy adults who are dissatisfied with their sleep: A randomized, placebo-controlled, double-blind crossover study..” Sleep medicine: X, 2026. PMID: 42571331 DOI: 10.1016/j.sleepx.2026.100196